SCHEMBL259344

SCHEMBL259344

O=C(Nc1c(C(=O)O)oc2ncccc12)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.50
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
ABCG2 Q9UNQ0 1/20 0.46
NPC1 O15118 5/20 0.46
MAPT P10636 4/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
POLB P06746 3/20 0.45
RAB9A P51151 3/20 0.45
MITF O75030 2/20 0.45
TP53 P04637 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
STAT1 P42224 1/20 0.44
P4HTM Q9NXG6 1/20 0.44
ADORA3 P0DMS8 1/20 0.43
MAPK1 P28482 1/20 0.43
CD40 P25942 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259200 0.90 KDR (0.49) KDRCYP11B1CYP11B2ABCG2NPC1
SCHEMBL259193 0.88 RAB9A (0.53) KDRABCG2NPC1MAPTKDM4E
SCHEMBL3728067 0.88 KDR (0.47) KDRCYP11B1CYP11B2ABCG2NPC1
SCHEMBL259335 0.86 ALDH1A1 (0.53) KDRNPC1MAPTKDM4EMEN1
SCHEMBL259197 0.85 KDM4E (0.50) KDRCYP11B1CYP11B2NPC1MAPT
SCHEMBL259192 0.81 MAPT (0.56) NPC1MAPTLMNAKMT2APOLB
SCHEMBL13298517 0.79 RAB9A (0.53) KDRABCG2NPC1MAPTKDM4E
SCHEMBL259376 0.76 ALDH1A1 (0.41) MAPTKDM4EMEN1KMT2APOLB
SCHEMBL259348 0.76 ALDH1A1 (0.66) KDRNPC1MAPTLMNAKDM4E
SCHEMBL259253 0.74 MEN1 (0.57) NPC1MAPTLMNAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KDR 628/4885CYP11B1 2585/4885CYP11B2 3088/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A KDR 628/4885CYP11B1 2585/4885CYP11B2 3088/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A KDR 628/4885CYP11B1 2585/4885CYP11B2 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.